Legacy Lung Cancer Trial: A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumabin Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer - Stand Up To Cancer

Blog

Posted October 14, 2019

Legacy Lung Cancer Trial: A Randomized Phase II Study of Epigenetic Priming with Azacitidine and Entinostat or Oral Azacitidine Alone Prior to Nivolumabin Subjects with Recurrent Metastatic Non-Small Cell Lung Cancer

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.